After more than ten years without significant therapeutic advancements in chronic obstructive pulmonary disease (COPD), patients with this progressive condition now have two new treatment options, with more likely to follow.
Regeneron and Sanofi recently announced that the FDA has broadened the use of the highly successful drug DUPIXENT to include the treatment of COPD. This approval increases DUPIXENT’s US indications to six, with its first approval occurring seven years ago for atopic dermatitis.
With this label expansion, DUPIXENT becomes the first biologic therapy available for COPD patients in the US. It is now approved as an add-on maintenance treatment fo...
